Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Unleashing the Underdogs: 3 Hidden Gems Set to Conquer the Market

In This Article:

Opportunities frequently appear out of nowhere when underdog businesses triumph against the odds thanks to shrewd planning and forethought. The companies on this list all embody the spirit of the underdog, even though they operate in different industries. Their strategic growth plans make all three of these companies hidden gem stocks that will conquer the market.

The first company is creating a lineup of exoskeletons that promises a large income stream, particularly if Medicare covers its devices. The second is leveraging urbanization trends by enhancing its operations through strategic investments and margin development. The third is bolstering its position in the energy industry through creative projects and long-term collaborations.

These businesses represent resilience, strategic insight and adaptability, all qualities necessary for survival and expansion in the current competitive environment. Rather than merely being singular success stories, these companies are poised for continued growth.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Rewalk Robotics (LFWD)

a worker with a tablet remotely operates a standalone robot arm. Get Rich with Robotics. Best Robotics Stocks to Buy. favorite robotics stocks
a worker with a tablet remotely operates a standalone robot arm. Get Rich with Robotics. Best Robotics Stocks to Buy. favorite robotics stocks

Source: Shutterstock

Lifeward, previously known as Rewalk Robotics (NASDAQ:LFWD), expects increased market penetration and top-line potential for its exoskeleton products once the Centers for Medicare & Medicaid Services (CMS) finalize the Home Health Rule in 2024. When Medicare starts to cover exoskeletons in its brace benefit category, there is a large opportunity for Lifeward’s market expansion. People with spinal cord injuries will have more access to ReWalk exoskeletons.

Some of Lifeward’s other strategic goals include developing stronger clinic-driven relationships, encouraging referrals and concentrating sales efforts on physicians. Lifeward seeks to effectively identify qualified patients for exoskeleton use by educating and supporting the medical community. This will allow the company to maximize Medicare coverage and spur top-line growth.

The Food and Drug Administration (FDA) recently approved a new version of the ReWalk exoskeleton, and Lifeward plans to introduce a new AlterG anti-gravity version as well. Lifeward hopes to lead the rehabilitation sector in technical innovation by integrating artificial intelligence (AI) into functional prototypes, enhancing exoskeleton usability and capabilities.

Lifeward projects revenue between $28 million and $32 million for 2024. While it may not be a stock you’ve heard of, LFWD might just be one of the hidden gem stocks that will conquer the market.